Bleomycin hypersensitivity in dyskeratosis congenita fibroblasts, lymphocytes, and transformed lymphoblasts.
We studied the responses of several dyskeratosis congenita (DC) cell lines to the DNA strand-cleaving and base-damaging agent bleomycin. Fibroblasts, peripheral blood lymphocytes, and transformed lymphoblasts of six DC patients and an obligate DC heterozygote showed more chromatid breaks than did respective controls exposed to various concentrations of bleomycin during the G2 phase of the cell cycle (P less than 0.0001). Unsynchronized DC fibroblasts in culture also showed decreased survival, compared to normals, following bleomycin treatment. DC lymphocytes treated with bleomycin for the final 24 h of culture showed more chromatid- and chromosome-type damage than did normals (P less than 0.0001) or G0-treated DC lymphocytes. Spontaneous chromosome breakage was normal in all six DC cell lines. The ability to distinguish affected and heterozygous DC cells without spontaneous chromosome instability from normals on the basis of their bleomycin hypersensitivity provides a marker for future studies of the pathogenesis of this disorder.
Pai
G S
GS
Department of Pediatrics, Medical University of South Carolina, Charleston 29425.
Yan
Y
Y
DeBauche
D M
DM
Stanley
W S
WS
Paul
S R
SR
D001761:Bleomycin / Q000494:pharmacology*; D002460:Cell Line; D002875:Chromosomes / Q000187:drug effects / Q000648:ultrastructure; D004249:DNA Damage; D004342:Drug Hypersensitivity / Q000473:pathology*; D005260:Female; D005347:Fibroblasts / Q000187:drug effects* / Q000648:ultrastructure; D008040:Genetic Linkage; D006801:Humans; D015603:Keratinocytes / Q000502:physiology; D007642:Keratosis / Q000151:congenital / Q000235:genetics / Q000473:pathology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects* / Q000648:ultrastructure; D008297:Male; D013577:Syndrome; D014960:X Chromosome
D001761:Bleomycin